Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Vertex Skips a Beat

Early this month, a release of competitors' data caused Vertex Pharmaceuticals' (Nasdaq: VRTX  ) stock to plummet. Today, it was news about a collaborator's clinical trial that caused the Rule Breakers stock to fall.

Yesterday evening, Vertex and Merck (NYSE: MRK  ) announced that they were suspending enrollment in their phase 2 clinical trial for testing the leukemia treatment MK-0457. One patient was observed with a QTc prolongation, a heart condition that results in irregular heartbeat and could result in a heart attack. It's not clear that the drug caused the condition, and patients enrolled in the trial will continue to be dosed, so the drug is far from dead.

Vertex clearly has a lot more riding on this compound than Merck does. Merck is set to pay up to $350 million in milestones if MK-0457 makes it through trials and receives an FDA approval -- not to mention the royalties once the drug is on the market.

MK-0457 is part of Vertex's and Merck's collaboration to target Aurora kinase, a protein that's required for cells to grow and therefore a perfect target for anti-cancer compounds. One compound in the collaboration has been dropped because of a lack of efficacy, but the duo plans to start another, VX-689, in a phase 1 trial early next year.

Vertex's shares have been in steady decline since competitors like Schering-Plough (NYSE: SGP  ) released data on compounds that will compete with Vertex's hepatitis C virus (HCV) drug telaprevir to become the next HCV blockbuster.

As my Foolish colleague Brian Lawler pointed out, there's still plenty of space in the HVC marketplace for multiple drugs. Combine the two partially unjustified drops in stock price, and you've got a drug developer with a serious markdown just in time for Christmas.

More Foolishness on tumors:

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 540648, ~/Articles/ArticleHandler.aspx, 10/26/2016 5:16:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
MRK $60.87 Down -1.08 -1.74%
Merck and Co. CAPS Rating: ****
VRTX $78.71 Down +0.00 +0.00%
Vertex Pharmaceuti… CAPS Rating: ****
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****